Comparative efficacy of two leading candidate ricin toxin A subunit vaccines in mice

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 789-794

  O'Hara, Joanne M ^a,b   Brey III, Robert N ^c   Mantis, Nicholas J ^a,b  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY AT ALBANY   (United States)

^c Soligenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMINO ACID; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; RICIN; RICIN TOXIN A SUBUNIT VACCINE; RIVAX VACCINE; RVEC VACCINE; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INTOXICATION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTITOXINS; EPITOPE MAPPING; FEMALE; MICE; MICE, INBRED BALB C; POISONING; RICIN; SURVIVAL ANALYSIS; VACCINES, SUBUNIT;

EID: 84878303015     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00098-13     Document Type: Article

References (34)

1. Endo Y, Tsurugi K. 1987. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 262:8128-8130. (Pubitemid 17104265)
2. Rutenber E, Ready M, Robertus JD. 1987. Structure and evolution of ricin B chain. Nature 326:624-626. (Pubitemid 17051336)
3. Franz D, Jaax N. 1997. Ricin toxin, p 631-642. In Zajtchuk R (ed), Textbook of military medicine. Borden Institute, Washington, DC.
4. Radosavljevic V, Belojevic G. 2009. A new model of bioterrorism risk assessment. Biosecur. Bioterror. 7:443-451.
5. Reisler RB, Smith LA. 2012. The need for continued development of ricin countermeasures. Adv. Prev. Med. 2012:149737. doi:10.1155/2012/149737.
6. Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, Pincus SH. 2004. Immunological characteristics associated with the protective efficacy of antibodies to ricin. J. Immunol. 172:6221-6228. (Pubitemid 38621228)
7. Yermakova A, Mantis NJ. 2011. Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB). Vaccine 29:7925-7935.
8. Smallshaw JE, Vitetta ES. 2012. Ricin vaccine development. Curr. Top. Microbiol. Immunol. 357:259-272.
9. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES. 2002. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20:3422-3427. (Pubitemid 35245826)
10. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, Vitetta ES. 2003. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. 21:387-391. (Pubitemid 36397658)
11. Carra JH, Wannemacher RW, Tammariello RF, Lindsey CY, Dinterman RE, Schokman RD, Smith LA. 2007. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 25:4149-4158. (Pubitemid 46635951)
12. McHugh CA, Tammariello RF, Millard CB, Carra JH. 2004. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci. 13:2736-2743. (Pubitemid 39274641)
13. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB. 2004. Finding a new vaccine in the ricin protein fold. Protein Eng. Des. Sel. 17:391-397. (Pubitemid 39093520)
14. O'Hara JM, Neal LM, McCarthy EA, Kasten-Jolly JA, Brey RN, III, Mantis NJ. 2010. Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28:7035-7046.
15. Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES. 2010. Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine 28:5315-5322.
16. Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES. 2005. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23:4775-4784. (Pubitemid 41557328)
17. Smallshaw JE, Richardson JA, Vitetta ES. 2007. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25:7459-7469. (Pubitemid 47484003)
18. Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R, Schindler J. 2006. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc. Natl. Acad. Sci. U. S. A. 103:2268-2273. (Pubitemid 43271659)
19. Vitetta ES, Smallshaw JE, Schindler J. 2012. Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin. Vaccine Immunol. 19:1697-1699.
20. McLain DE, Horn TL, Detrisac CJ, Lindsey CY, Smith LA. 2011. Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits. Int. J. Toxicol. 30:143-152.
21. McLain DE, Lewis BS, Chapman JL, Wannemacher RW, Lindsey CY, Smith LA. 2012. Protective effect of two recombinant ricin subunit vaccines in the New Zealand White rabbit subjected to a lethal aerosolized ricin challenge: survival, immunological response and histopathological findings. Toxicol. Sci. 126:72-83.
22. Meagher MM, Seravalli JG, Swanson ST, Ladd RG, Khasa YP, Inan M, Harner JC, Johnson SK, Van Cott K, Lindsey C, Wannemacher R, Smith LA. 2011. Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc. Biotechnol. Prog. 27:1036-1047.
23. Porter A, Phillips G, Smith L, Erwin-Cohen R, Tammariello R, Hale M, Dasilva L. 2011. Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay. Toxicon 58:68-75.
24. Peek LJ, Brey RN, Middaugh CR. 2007. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J. Pharm. Sci. 96:44-60. (Pubitemid 46087338)
25. Pincus SH, Eng L, Cooke CL, Maddaloni M. 2002. Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis. Comp. Med. 52:530-533. (Pubitemid 36091703)
26. Neal LM, O'Hara J, Brey RN, III, Mantis NJ. 2010. A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect. Immun. 78:552-561.
27. Thomas JC, O'Hara JM, Hu L, Gao FP, Joshi SB, Volkin DB, Brey RN, Fang J, Karanicolas J, Mantis NJ, Middaugh CR. 2013. Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen. Hum. Vaccin. Immunother. 9:740-748.
28. Hem SL, Hogenesch H. 2007. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6:685-698. (Pubitemid 47607846)
29. Hem SL, HogenEsch H, Middaugh CR, Volkin DB. 2010. Preformulation studies: the next advance in aluminum adjuvant-containing vaccines. Vaccine 28:4868-4870.
30. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL. 2012. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin. Vaccine Immunol. 19:1465-1473.
31. Lemley PV, Amanatides P, Wright DC. 1994. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 13:417-421. (Pubitemid 24351544)
32. Vance DJ, Mantis NJ. 2012. Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant alpha-helix in ricin toxin's enzymatic subunit. Toxicon 60:874-877.
33. Compton JR, Legler PM, Clingan BV, Olson MA, Millard CB. 2011. Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen. Proteins 79:1048-1060.
34. Legler PM, Brey RN, Smallshaw JE, Vitetta ES, Millard CB. 2011. Structure of RiVax: a recombinant ricin vaccine. Acta Crystallogr. D Biol. Crystallogr. 67:826-830.